Ahmed Elshafei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7416112/publications.pdf

Version: 2024-02-01

840776 677142 27 485 11 22 citations h-index g-index papers 27 27 27 709 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Copeptin: a neuroendocrine biomarker of COVID-19 severity. Biomarkers in Medicine, 2022, , .	1.4	8
2	Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?. Prostate Cancer and Prostatic Diseases, 2021, 24, 507-513.	3.9	0
3	MicroRNA-567 inhibits cell proliferation and induces cell apoptosis in A549 NSCLC cells by regulating cyclin-dependent kinase 8. Saudi Journal of Biological Sciences, 2021, 28, 2581-2590.	3.8	74
4	T-Natural Killers and Interferon Gamma/Interleukin 4 in Augmentation of Infection in Foot Ulcer in Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 1897-1908.	2.4	7
5	RAAS, ACE2 and COVID-19; a mechanistic review. Saudi Journal of Biological Sciences, 2021, 28, 6465-6470.	3.8	17
6	The clinical value of ficolin-3 gene polymorphism in rheumatic heart disease. An Egyptian adolescents study. BMC Research Notes, 2021, 14, 36.	1.4	3
7	Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e260-e265.	1.9	17
8	The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy. Urology, 2020, 137, 115-120.	1.0	1
9	Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze. Clinical Genitourinary Cancer, 2019, 17, e831-e836.	1.9	12
10	Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate. Clinical Genitourinary Cancer, 2018, 16, e477-e482.	1.9	4
11	Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. Journal of Urology, 2018, 199, 445-452.	0.4	9
12	Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry. Clinical Genitourinary Cancer, 2018, 16, e1073-e1076.	1.9	2
13	Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. Journal of Endourology, 2017, 31, 497-501.	2.1	5
14	The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study. Tumor Biology, 2017, 39, 101042831770576.	1.8	42
15	Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance. Journal of Urology, 2017, 198, 591-599.	0.4	36
16	Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation. Prostate, 2017, 77, 1446-1450.	2.3	12
17	Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy. Journal of Urology, 2017, 197, 84-89.	0.4	8
18	External validation of a PCAâ€3â€based nomogram for predicting prostate cancer and highâ€grade cancer on initial prostate biopsy. Prostate, 2016, 76, 1019-1023.	2.3	9

AHMED ELSHAFEI

#	Article	IF	CITATIONS
19	Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. Journal of Endourology, 2016, 30, 624-631.	2.1	15
20	More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2016, 195, 1767-1772.	0.4	13
21	Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. Journal of Endourology, 2016, 30, 43-48.	2.1	30
22	A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. Prostate, 2015, 75, 1447-1453.	2.3	13
23	Transrectal Saturation Biopsy Improves Risk Stratification (Reclassification) of Patients with Prostate Cancer on Active Surveillance. Urology Practice, 2015, 2, 115-120.	0.5	0
24	Low risk patients benefit from extreme anterior apical sampling on initial biopsy for prostate cancer diagnosis. Prostate, 2014, 74, 1183-1188.	2.3	6
25	Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy. Journal of Urology, 2014, 191, 1743-1748.	0.4	98
26	Definition of Biochemical Success Following Primary Whole Gland Prostate Cryoablation. Journal of Urology, 2014, 192, 1380-1384.	0.4	28
27	The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy. Prostate, 2013, 73, 1796-1802.	2.3	16